Key Points
- Establishment Labs director Quiros Juan Jose Chacon sold 105,000 shares on May 6 at an average price of $75.42, generating about $7.9 million and reducing his stake by 10.17%.
- The filing follows a series of recent insider sales by Chacon, including multiple transactions in late March and April, suggesting ongoing selling activity in the stock.
- The company reported mixed quarterly results, with revenue of $59.88 million beating expectations but EPS of -$0.45 missing estimates; shares were down 0.4% and the stock has a Wall Street consensus rating of Moderate Buy.
Establishment Labs Holdings Inc. (NASDAQ:ESTA - Get Free Report) Director Quiros Juan Jose Chacon sold 105,000 shares of Establishment Labs stock in a transaction that occurred on Wednesday, May 6th. The stock was sold at an average price of $75.42, for a total transaction of $7,919,100.00. Following the completion of the transaction, the director directly owned 927,504 shares in the company, valued at $69,952,351.68. This represents a 10.17% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Quiros Juan Jose Chacon also recently made the following trade(s):
- On Monday, May 4th, Quiros Juan Jose Chacon sold 7,751 shares of Establishment Labs stock. The stock was sold at an average price of $70.48, for a total transaction of $546,290.48.
- On Friday, May 1st, Quiros Juan Jose Chacon sold 67,249 shares of Establishment Labs stock. The stock was sold at an average price of $70.78, for a total transaction of $4,759,884.22.
- On Monday, April 27th, Quiros Juan Jose Chacon sold 2,180 shares of Establishment Labs stock. The stock was sold at an average price of $66.26, for a total transaction of $144,446.80.
- On Friday, April 24th, Quiros Juan Jose Chacon sold 30,178 shares of Establishment Labs stock. The stock was sold at an average price of $65.78, for a total transaction of $1,985,108.84.
- On Thursday, April 23rd, Quiros Juan Jose Chacon sold 42,642 shares of Establishment Labs stock. The stock was sold at an average price of $65.43, for a total transaction of $2,790,066.06.
- On Tuesday, April 14th, Quiros Juan Jose Chacon sold 37,500 shares of Establishment Labs stock. The stock was sold at an average price of $65.23, for a total transaction of $2,446,125.00.
- On Wednesday, March 25th, Quiros Juan Jose Chacon sold 3,575 shares of Establishment Labs stock. The stock was sold at an average price of $60.08, for a total transaction of $214,786.00.
- On Monday, March 23rd, Quiros Juan Jose Chacon sold 33,925 shares of Establishment Labs stock. The stock was sold at an average price of $60.39, for a total transaction of $2,048,730.75.
Establishment Labs Stock Down 0.4%
NASDAQ ESTA opened at $71.77 on Friday. The company has a debt-to-equity ratio of 10.51, a current ratio of 3.04 and a quick ratio of 2.00. The company's 50 day simple moving average is $65.27 and its 200 day simple moving average is $66.59. Establishment Labs Holdings Inc. has a 12 month low of $33.30 and a 12 month high of $83.31. The company has a market capitalization of $2.11 billion, a P/E ratio of -48.17 and a beta of 1.12.
Establishment Labs (NASDAQ:ESTA - Get Free Report) last released its earnings results on Wednesday, May 6th. The company reported ($0.45) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.10). The business had revenue of $59.88 million during the quarter, compared to the consensus estimate of $57.40 million. Establishment Labs had a negative return on equity of 202.78% and a negative net margin of 19.05%.The firm's revenue for the quarter was up 44.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.70) earnings per share. Equities research analysts expect that Establishment Labs Holdings Inc. will post -0.83 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Establishment Labs
Institutional investors have recently bought and sold shares of the business. KBC Group NV acquired a new stake in Establishment Labs during the 1st quarter worth about $28,000. Kestra Advisory Services LLC acquired a new stake in Establishment Labs during the 4th quarter worth about $47,000. Quarry LP acquired a new stake in Establishment Labs during the 3rd quarter worth about $34,000. State of Wyoming acquired a new stake in Establishment Labs during the 3rd quarter worth about $71,000. Finally, MV Capital Management Inc. acquired a new stake in Establishment Labs during the 4th quarter worth about $146,000. 72.91% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
A number of brokerages recently weighed in on ESTA. Wall Street Zen cut Establishment Labs from a "buy" rating to a "hold" rating in a research note on Saturday, March 28th. BTIG Research lifted their price target on Establishment Labs from $88.00 to $90.00 and gave the stock a "buy" rating in a research note on Thursday. Needham & Company LLC lifted their price target on Establishment Labs from $84.00 to $86.00 and gave the stock a "buy" rating in a research note on Tuesday, February 24th. Canaccord Genuity Group lifted their price target on Establishment Labs from $85.00 to $90.00 and gave the stock a "buy" rating in a research note on Thursday, February 26th. Finally, Stephens lifted their price target on Establishment Labs from $85.00 to $90.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 25th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $87.14.
View Our Latest Stock Report on Establishment Labs
Establishment Labs Company Profile
(
Get Free Report)
Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company's proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.
The company's flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
